0001410708
2014-08-01
2014-10-31
0001410708
2014-11-28
0001410708
2014-10-31
0001410708
2014-07-31
0001410708
2013-08-01
2013-10-31
0001410708
2006-08-23
2014-10-31
0001410708
2013-07-31
0001410708
2013-10-31
0001410708
2006-08-22
0001410708
2007-07-15
0001410708
2008-05-01
0001410708
2010-02-25
0001410708
2012-10-31
0001410708
2010-10-31
0001410708
2010-09-30
0001410708
2012-05-01
0001410708
2011-12-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Emo Capital Corp.
0001410708
10-Q
2014-10-31
false
--07-31
No
No
No
Smaller Reporting Company
Q1
2014
35500000
35000000
35000000
5000000.
0
0
44439
38121
13425
13425
57864
51546
27000
27000
100000
100000
2000
30000
100000
150
-100000
-100000
-89864
-83546
-57864
-51546
0
0
5000
5000
0.001
0.001
0.001
0.01
.001
0.20
.01
125000000
125000000
125000000
1500
35500000
35500000
14000000
21000000
5149
84461
2054
350
407
1169
2591
6318
89864
-6318
-89864
0.00
0.00
35500000
35500000
-6318
-89864
6318
44439
-45425
13425
32000
45425
0
0
<p style="margin: 0pt"></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>1. NATURE AND CONTINUANCE OF OPERATIONS</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company is a development stage company, which was incorporated
in the State of Nevada, United States of America on August 23, 2006. The Company intends to commence operations in health and beauty
care through the utilization of the web.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">These financial statements have been prepared on a going
concern basis. The Company has accumulated a deficit of $89,864 since inception and has yet to achieve profitable operations and
further losses are anticipated in the development of its business, raising substantial doubt about the Company's ability to continue
as a going concern. Its ability to continue as a going concern is dependent upon the ability of the Company to generate profitable
operations in the future and or to obtain the necessary financing to meet its obligations and repay its liabilities arising from
normal business operations when they come due. Management plans to continue to provide for its working capital needs by seeking
loans from its shareholder. These financial statements do not include any adjustments to the recoverability and classification
of assets, or the amount and classification of liabilities that may be necessary should the Company be unable to continue as a
going concern.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The company's year-end is July 31.</p>
<p style="margin: 0pt"></p>
89864
<p style="margin: 0pt"></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The financial statements of the Company have been prepared
in accordance with accounting principles generally accepted in the United States of America. Because a precise determination of
many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves
the use of estimates, which have been made using careful judgment. Actual results may vary from these estimates.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The financial statements have, in management's opinion, been
properly prepared within the framework of the significant accounting policies summarized below:</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Cash and Cash Equivalents</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Cash equivalents comprise certain highly liquid instruments
with maturities of three months or less when purchased. As at October 31, 2014, there were Cash and Cash Equivalents equal to $0.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Development Stage Company</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company complies with the FASB Accounting Standards Codification
(ASC) Topic 915 Development Stage Entities and the Securities and Exchange Commission Exchange Act 7 for its characterization of
the Company as development stage.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Impairment of Long Lived Assets</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Long-lived assets are reviewed for impairment in accordance
with ASC Topic 360, "Accounting for the Impairment or Disposal of Long- lived Assets". Under ASC Topic 360, long-lived
assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be
recoverable. An impairment charge is recognized or the amount, if any, which the carrying value of the asset exceeds the fair value.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Foreign Currency Translation</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company is located and operating outside of the United
States of America. It maintains its accounting records in U.S. Dollars, as follows:</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">At the transaction date, each asset, liability, revenue,
and expense is translated into U.S. dollars by the use of exchange rates in effect at that date. At the period end, monetary assets
and liabilities are remeasured by using the exchange rate in effect at that date. The resulting foreign exchange gains and losses
are included in operations.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company's currency exposure is insignificant and immaterial
and we do not use derivative instruments to reduce its potential exposure to foreign currency risk.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Financial Instruments</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The carrying value of the Company's financial instruments
consisting of cash equivalents and accounts payable and accrued liabilities approximates their fair value because of the short
maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant
interest, currency or credit risks arising from these financial instruments.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Income Taxes</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company uses the assets and liability method of accounting
for income taxes in accordance with FASB Topic 740 “Income Taxes".  Under this method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements
carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
recovered or settled.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Basic and Diluted Net Loss Per Share</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In accordance with FASB Topic 260, "Earnings Per Share',
the basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number
of common shares outstanding. Diluted net loss per common share is computed similar to basic net loss per common share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common shares had been issued and if the additional common shares were dilutive. As at October 31, 2014, diluted net loss per share
is equivalent to basic net loss per share.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Stock Based Compensation</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company accounts for stock options and similar equity
instruments issued in accordance with ASC Topic 718 Compensation-Stock Compensation.  Accordingly, compensation costs attributable
to stock options or similar equity instruments granted are measured at the fair value at the grant date, and expensed over the
expected vesting period.   Transactions in which goods or services are received in exchange for the issuance of equity
instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measurable. ASC Topic 718- Compensation requires excess tax benefits be reported as a financing
cash inflow rather than as a reduction of taxes paid.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company did not grant any stock options during the period
ended October 31, 2014.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Comprehensive Income</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company adopted Statement of Financial Accounting Standards
No. 130 (SFAS 130), Reporting Comprehensive Income, which establishes standards for reporting and display of comprehensive income,
its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. 
Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. </p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company has no elements of "other comprehensive
income" during the period ended October 31, 2014.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Advertising Expenses</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The company expenses advertising costs as incurred. The advertising
expense incurred by the company is $1,169 during the period ended October 31, 2014.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>New Accounting Standards</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Management does not believe that any recently issued, but
not yet effective accounting standards if currently adopted could have a material effect on the accompanying financial statements.</p>
<p style="margin: 0pt"></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Cash and Cash Equivalents</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Cash equivalents comprise certain highly liquid instruments
with maturities of three months or less when purchased. As at October 31, 2014, there were Cash and Cash Equivalents equal to $0.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Development Stage Company</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company complies with the FASB Accounting Standards Codification
(ASC) Topic 915 Development Stage Entities and the Securities and Exchange Commission Exchange Act 7 for its characterization of
the Company as development stage.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Impairment of Long Lived Assets</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Long-lived assets are reviewed for impairment in accordance
with ASC Topic 360, "Accounting for the Impairment or Disposal of Long- lived Assets". Under ASC Topic 360, long-lived
assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be
recoverable. An impairment charge is recognized or the amount, if any, which the carrying value of the asset exceeds the fair value.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Foreign Currency Translation</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company is located and operating outside of the United
States of America. It maintains its accounting records in U.S. Dollars, as follows:</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">At the transaction date, each asset, liability, revenue,
and expense is translated into U.S. dollars by the use of exchange rates in effect at that date. At the period end, monetary assets
and liabilities are remeasured by using the exchange rate in effect at that date. The resulting foreign exchange gains and losses
are included in operations.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company's currency exposure is insignificant and immaterial
and we do not use derivative instruments to reduce its potential exposure to foreign currency risk.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Financial Instruments</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The carrying value of the Company's financial instruments
consisting of cash equivalents and accounts payable and accrued liabilities approximates their fair value because of the short
maturity of these instruments. Unless otherwise noted, it is management's opinion that the Company is not exposed to significant
interest, currency or credit risks arising from these financial instruments.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Income Taxes</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company uses the assets and liability method of accounting
for income taxes in accordance with FASB Topic 740 “Income Taxes".  Under this method, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements
carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be
recovered or settled.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Basic and Diluted Net Loss Per Share</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In accordance with FASB Topic 260, "Earnings Per Share',
the basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted average number
of common shares outstanding. Diluted net loss per common share is computed similar to basic net loss per common share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential
common shares had been issued and if the additional common shares were dilutive. As at October 31, 2014, diluted net loss per share
is equivalent to basic net loss per share.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Stock Based Compensation</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company accounts for stock options and similar equity
instruments issued in accordance with ASC Topic 718 Compensation-Stock Compensation.  Accordingly, compensation costs attributable
to stock options or similar equity instruments granted are measured at the fair value at the grant date, and expensed over the
expected vesting period.   Transactions in which goods or services are received in exchange for the issuance of equity
instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments
issued, whichever is more reliably measurable. ASC Topic 718- Compensation requires excess tax benefits be reported as a financing
cash inflow rather than as a reduction of taxes paid.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company did not grant any stock options during the period
ended October 31, 2014.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Comprehensive Income</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company adopted Statement of Financial Accounting Standards
No. 130 (SFAS 130), Reporting Comprehensive Income, which establishes standards for reporting and display of comprehensive income,
its components and accumulated balances. The Company is disclosing this information on its Statement of Stockholders' Equity. 
Comprehensive income comprises equity except those resulting from investments by owners and distributions to owners. </p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The Company has no elements of "other comprehensive
income" during the period ended October 31, 2014.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Advertising Expenses</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">The company expenses advertising costs as incurred. The advertising
expense incurred by the company is $1,169 during the period ended October 31, 2014.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>New Accounting Standards</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Management does not believe that any recently issued, but
not yet effective accounting standards if currently adopted could have a material effect on the accompanying financial statements.</p>
<p style="margin: 0pt"></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>3. CAPITAL STOCK</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">On July 15, 2007, the Company issued 14,000,000 common shares
at $0.001 per share to the sole director of the Company for total proceeds of $2,000.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In May 2008, the Company issued 21,000,000 common shares
at $0.01 per share to subscribers for total proceeds of $30,000.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">On February 25, 2010, the Company amended its Articles of
incorporation and authorized 125,000,000 shares of common stock, at $.001 par value of which 35,000,000 were issued and outstanding
as of October 31, 2012.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">On October 31, 2010, the Stockholder's of the Company authorized
the Forward Stock Split of our issued and outstanding Common Stock on a seven for one (7:1) basis. The Forward Stock Split became
effective on October 31, 2010. As a result of the Forward Stock Split, the Company increased its issued and outstanding shares
of the Common Stock to 35,000,000 from 5,000,000.</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In May 2012, the Company subscribed 500,000 restricted common
shares at $0.20 per share to a shareholder for a subscription receivable of $100,000.</p>
500000
<p style="margin: 0pt"></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>4. RELATED PARTY TRANSACTIONS</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">A series of shareholder loans were made from August 23, 2006 to
October 31, 2014 totaling $13,425. A balance of $13,425 is still outstanding as of October 31, 2014, without interest and
fixed term of repayment. The loan is due at demand.</p>
<p style="margin: 0pt"></p>
13425
<p style="margin: 0pt"></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>5. SUBSIDIARIES</b></p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">On December 22, 2011 the Company incorporated Nu Vitality
Labs Inc., in the State of Nevada as a wholly owned subsidiary of Emo Capital Corp. Nu Vitality Labs Inc., has authorized common
shares of 1500 shares par value .01 and all authorized shares have been issued to EMO Capital Corp. Emo Capital Corp. paid $150
for the shares of Nu Vitality Labs Inc. The attached financial statements were prepared using the consolidation method to account
for the 100% wholly owned subsidiary, Nu Vitality Labs Inc., and Emo Capital Corp. for the period ended October 31, 2014.</p>
<p style="margin: 0pt"></p>
21000000